查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591875

醫院感染治療藥物市場：依藥物類型、感染疾病- 全球預測 2025-2030

Hospital Infection Therapeutics Market by Drug Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Infections (Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年醫院感染治療藥物市場規模為59億美元，預計2024年將達63.8億美元，複合年成長率為8.27%，2030年將達到102.9億美元。

醫院感染治療藥物市場是醫療保健行業的一個專門部門，專注於醫院環境中發生的感染疾病的治療和管理。這些感染疾病通常稱為醫院感染或醫療保健相關感染 (HAIs)，包括 MRSA、艱難梭菌和血流感染等疾病。 HAI 會導致住院時間延長、醫療費用增加和死亡率增加，從而增加了對此類治療的需求。醫院感染治療藥物包括抗生素、抗病毒藥物和抗真菌藥物，主要由專門從事感染疾病的臨床醫生在醫院環境中使用。最終用途包括醫院、診所和專門的感染疾病治療中心。影響該市場的關鍵成長要素包括老年人口的增加、外科手術數量的增加以及導致早期檢測的診斷工具的進步。此外，政府旨在預防和控制感染的措施正在創造市場擴張的潛力。生物技術的最新創新和人工智慧在藥物發現中的出現提供了充滿希望的機會。然而，市場成長面臨抗生素抗藥性和嚴格的監管核准等挑戰，這可能會減緩產品的推出和創新。該市場的創新可能集中在開發新的抗菌藥物、噬菌體療法等替代療法以及提高治療效果的快速診斷測試。製藥公司與研究機構之間的策略聯盟有助於克服研發成本高等限制。透過投資研發，特別是針對患者獨特感染情況量身定做的個人化醫療方法，可以實現業務成長。此外，可以利用巨量資料分析來深入了解感染模式並最佳化治療性介入。市場競爭激烈，並受到對治療的持續需求的推動，需要靈活的創新來應對新出現的傳染病挑戰和監管發展。

主要市場統計
基準年[2023] 59億美元
預測年份 [2024] 63.8億美元
預測年份 [2030] 102.9億美元
複合年成長率（%） 8.27%

市場動態：快速發展的醫院感染治療市場的關鍵市場洞察

供需的動態交互作用正在改變醫院感染藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病增加導致老年人口增加
    • 迅速重視感染控制政策
    • 完善報銷政策
  • 市場限制因素
    • 對產品召回的擔憂
  • 市場機會
    • 加大醫院感染治療藥物研發投入
    • 政府對藥品/藥物的有利核准
  • 市場挑戰
    • 關於醫院感染的嚴格監管要求

波特五力：駕馭醫院感染藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解醫院感染治療藥物市場的外部影響

外部宏觀環境因素在塑造醫院感染治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解醫院感染治療藥物市場的競爭狀況

醫院感染治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 醫院感染治療藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估醫院感染治療藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃醫院感染治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對醫院感染治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病增加導致老年人口增加
      • 對感染控制政策的重視正在迅速增加
      • 改進退款政策
    • 抑制因素
      • 對產品召回的擔憂
    • 機會
      • 加大醫院感染治療藥物研發投入
      • 政府核准藥品
    • 任務
      • 嚴格醫院感染監管要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥品類型分類的醫院感染治療藥品市場

  • 抗生素
  • 抗真菌藥物
  • 抗病毒藥物

第7章感染疾病醫院感染治療藥品市場

  • 血流感染疾病
  • 胃腸道疾病
  • 院內肺炎
  • 手術部位感染
  • 尿道感染

第8章北美和南美醫院感染治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太醫院感染治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲醫院感染治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
Product Code: MRR-43127F7278A5

The Hospital Infection Therapeutics Market was valued at USD 5.90 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 8.27%, to USD 10.29 billion by 2030.

The Hospital Infection Therapeutics market is a specialized segment of the healthcare industry focused on the treatment and management of infections acquired in hospital settings. These infections, often termed nosocomial or healthcare-associated infections (HAIs), include conditions such as MRSA, C. difficile, and bloodstream infections. The necessity for such therapeutics has risen due to the increasing incidence of HAIs, which contribute to prolonged hospital stays, higher healthcare costs, and significant mortality rates. The application of hospital infection therapeutics spans antibiotics, antiviral, and antifungal agents, used primarily in hospital environments by clinicians specializing in infectious diseases. End-use sectors include hospitals, clinics, and specialized infection treatment centers. Key growth factors influencing this market include the growing geriatric population, increasing surgical procedures, and advancements in diagnostic tools leading to early detection. Moreover, government initiatives aimed at infection prevention and control create potential for market expansion. Recent biotechnology innovations and the advent of AI in drug discovery present promising opportunities. However, market growth faces challenges such as antibiotic resistance and stringent regulatory approvals, which can delay product launches and innovation. Innovations in this market are likely to focus on developing new antimicrobial agents, alternative therapies like phage therapy, and rapid diagnostic tests that enhance treatment efficacy. Strategic collaborations among pharmaceutical companies and research institutions can help overcome limitations such as high R&D costs. Business growth is feasible through investments in R&D, especially in personalized medicine approaches tailored to patient-specific infection profiles. Additionally, leveraging big data analytics can provide insights into infection patterns, optimizing therapeutic interventions. The market is competitive, driven by continuous need for improved therapeutics, and necessitates agile innovation to address emerging infection challenges and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 5.90 billion
Estimated Year [2024] USD 6.38 billion
Forecast Year [2030] USD 10.29 billion
CAGR (%) 8.27%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hospital Infection Therapeutics Market

The Hospital Infection Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population with the increase in the number of chronic diseases
    • Rapidly growing emphasis on infection control policies
    • Improvements in reimbursement policies
  • Market Restraints
    • Concerns related to product recalls
  • Market Opportunities
    • Increasing investments in R&D on hospital infection therapeutics
    • Favorable drug and medication approvals by government
  • Market Challenges
    • Stringent Regulatory Requirements for Hospital Acquired Infection

Porter's Five Forces: A Strategic Tool for Navigating the Hospital Infection Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hospital Infection Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hospital Infection Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hospital Infection Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hospital Infection Therapeutics Market

A detailed market share analysis in the Hospital Infection Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hospital Infection Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hospital Infection Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hospital Infection Therapeutics Market

A strategic analysis of the Hospital Infection Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hospital Infection Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., and Spero Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Hospital Infection Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
  • Based on Infections, market is studied across Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia, Surgical Site Infections, and Urinary Tract Infection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population with the increase in the number of chronic diseases
      • 5.1.1.2. Rapidly growing emphasis on infection control policies
      • 5.1.1.3. Improvements in reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns related to product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D on hospital infection therapeutics
      • 5.1.3.2. Favorable drug and medication approvals by government
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory Requirements for Hospital Acquired Infection
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hospital Infection Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antibacterial Drugs
  • 6.3. Antifungal Drugs
  • 6.4. Antiviral Drugs

7. Hospital Infection Therapeutics Market, by Infections

  • 7.1. Introduction
  • 7.2. Bloodstream Infections
  • 7.3. Gastrointestinal Disorders
  • 7.4. Hospital-Acquired Pneumonia
  • 7.5. Surgical Site Infections
  • 7.6. Urinary Tract Infection

8. Americas Hospital Infection Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hospital Infection Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hospital Infection Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AstraZeneca PLC
  • 4. Basilea Pharmaceutica Ltd.
  • 5. Bayer AG
  • 6. Bristol Myers Squibb Company
  • 7. Daiichi Sankyo Company, Limited
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Gilead Sciences Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services Inc.
  • 12. Merck & Co., Inc.
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Spero Therapeutics

LIST OF FIGURES

  • FIGURE 1. HOSPITAL INFECTION THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HOSPITAL INFECTION THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBACTERIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SURGICAL SITE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 103. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023